Therapy of leishmaniasis in France: Consensus on proposed guidelines;Traitement des leishmanioses en France: Proposition d'un référentiel consensuel

Presse Medicale

Volumn 40, Issue 2, 2011, Pages 173-184

  Buffet, Pierre A ^a,f   Rosenthal, Éric ^b   Gangneux, Jean Pierre ^c   Lightburne, Edward ^d   Couppié, Pierre ^e   Morizot, Gloria ^f   Lachaud, Laurence ^g   Marty, Pierre ^b   Dedet, Jean Pierre ^g  

^a SORBONNE UNIVERSITÉ   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d LAVERAN MILITARY TEACHING HOSPITAL   (France)

^e UNIVERSITÉ DES ANTILLES ET DE LA GUYANE   (France)

^f INSTITUT PASTEUR   (France)

^g UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; MEGLUMINE ANTIMONATE; PAROMOMYCIN; PENTAMIDINE;

CONSENSUS DEVELOPMENT; CRYOTHERAPY; DRUG EFFICACY; FRANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; LEISHMANIA BRAZILIENSIS; LEISHMANIA PANAMENSIS; LEISHMANIASIS; LOCAL THERAPY; MEDICAL SOCIETY; PRACTICE GUIDELINE; SHORT COURSE THERAPY; SHORT SURVEY; SKIN LEISHMANIASIS; SYSTEMIC THERAPY; TREATMENT DURATION; VISCERAL LEISHMANIASIS;

FRANCE; HUMANS; LEISHMANIASIS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL;

EID: 79551562922     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2010.09.023     Document Type: Short Survey

References (88)

1. Couppie P., Clyti E., Sobesky M., Bissuel F., Del Giudice P., Sainte-Marie D., et al. Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004, 151:1165-1171.
2. Marty P., Pomares-Estran C., Hasseine L., Delaunay P., Haas H., Rosenthal E. Actualités sur les leishmanioses en France Arch Pediatr 2009, 16 Suppl 2:S96-100.
3. Pratlong F., Rioux J.A., Marty P., Faraut-Gambarelli F., Dereure J., Lanotte G., et al. Isoenzymatic analysis of 712 strains of Leishmania infantum in the south of France and relationship of enzymatic polymorphism to clinical and epidemiological features. J Clin Microbiol 2004, 42:4077-4082.
4. Pratlong F., Dereure J., Ravel C., Lamy P., Balard Y., Serres G., et al. Geographical distribution and epidemiological features of Old World cutaneous leishmaniasis foci, based on the isoenzyme analysis of 1048 strains. Trop Med Int Health 2009, 14:1071-1085.
5. Morizot G, Delgiudice P, Caumes E, Laffitte E, Marty P, Dupuy A, et al. Healing of Old World cutaneous leishmaniasis in travellers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007:76;48-52.
6. Dedet J.P. Cutaneous leishmaniasis in French Guiana: a review. Am J Trop Med Hyg 1990, 43:25-28.
7. Buffet P., Deray G., Grogl M., Martinez F., Jacobs C. Tolerance and pharmacokinetics of antimony in a patient with renal failure. Nephrol Dial Transplant 1995, 10:1477.
8. Navin T.R., Arana B.A., Arana F.E., Berman J.D., Chajon J.F. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992, 165:528-534.
9. Buffet P., Caumes E., Gentilini M. Traitement de la leishmaniose cutanée localisée. Ann Dermatol Venereol 1994, 121:503-511.
10. Gangneux J.P. Traitement de la leishmaniose viscérale: modalités récentes. Presse Med 1999, 28:2057-2066.
11. Gangneux J.P., Marty P. Traitement de la leishmaniose viscérale: le point sur l'intérêt et les limites de la miltéfosine. Sante 2001, 11:257-258.
12. Marty P., Rosenthal E. Treatment of visceral leishmaniasis: a review of current treatment practices. Expert Opin Pharmacother 2002, 3:1101-1108.
13. Rosenthal E., Marty P. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 2003, 49:61-68.
14. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003, 16:397-401.
15. Alvar J., Croft S., Olliaro P. Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 2006, 61:223-274.
16. Jeddi F., Caumes E., Thellier M., Jauréguiberry S., Mazier D., Buffet P. Drug hypersensitivity syndrome induced by meglumine antimoniate. Am J Trop Med Hyg 2009, 80:939-940.
17. Andersen E.M., Cruz-Saldarriaga M., Llanos-Cuentas A., Luz-Cjuno M., Echevarria J., Miranda C., et al. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am J Trop Med Hyg 2005, 72:133-137.
18. Alvar J., Aparicio P., Aseffa A., Den Boer M., Cañavate C., Dedet J.P., et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008, 21:334-359.
19. den Boer M.L., Alvar J., Davidson R.N., Ritmeijer K., Balasegaram M. Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs 2009, 14:395-410.
20. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010;362:504-12.
21. Rosenthal E., Delaunay P., Jeandel P.Y., Haas H., Pomares-Estran C., Marty P. Le traitement de la leishmaniose viscérale en Europe en 2009. Place de l'amphotericine B liposomale. Med Mal Infect 2009, 39:741-744.
22. Berman J, Bryceson AD, Croft S, Engel J, Gutteridge W, Karbwang J, et al. Miltefosine: issues to be addressed in the future. Trans R Soc Trop Med Hyg 2006; 100 Suppl 1:S41-44.
23. Bhattacharya S.K., Sinha P.K., Sundar S., Thakur C.P., Jha T.K., Pandey K., et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007, 196:591-598.
24. Sundar S., Jha T.K., Thakur C.P., Sinha P.K., Bhattacharya S.K. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med 2007, 356:2571-2581.
25. Soto J., Buffet P., Grogl M., Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994, 50:107-111.
26. Patel T.A., Lockwood D.N. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases. Trop Med Int Health 2009, 14:1064-1070.
27. Guerin P.J., Olliaro P., Sundar S., Boelaert M., Croft S.L., Desjeux P., et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002, 2:494-501.
28. Olliaro P.L., Guerin P.J., Gerstl S., Haaskjold A.A., Rottingen J.A., Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005, 5:763-774.
29. Bourgeois N, Bastien P, Reynes J, Makinson A, Rouanet I, Lachaud L. 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med 2010;11:670-3.
30. de Valliere S., Mary C., Joneberg J.E., Rotman S., Bullani R., Greub G., et al. AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 2009, 81:209-212.
31. Posada-Vergara M.P., Lindoso J.A., Tolezano J.E., Pereira-Chioccola V.L., Silva M.B., Goto H. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS. J Infect Dis 2005, 192:1819-1822.
32. Kerob D., Bouaziz J.D., Sarfati C., Pavie J., Vignon-Pennamen M.D., Menotti J., et al. First case of cutaneous reconstitution inflammatory syndrome associated with HIV infection and leishmaniasis. Clin Infect Dis 2006, 43:664-666.
33. Buffet P.A., Morizot G. La leishmaniose cutanée en France: vers la fin des traitements injectables ?. Bull Soc Pathol Exot 2003, 96:383-388.
34. Modabber F., Buffet P.A., Torreele E., Milon G., Croft S.L. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis 2007, 6:3.
35. Blum J.A., Hatz C.F. Treatment of cutaneous leishmaniasis in travelers 2009. J Travel Med 2009, 16:123-131.
36. Laguna F., Videla S., Jimenez-Mejias M.E., Sirera G., Torre-Cisneros J., Ribera E., et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 2003, 52:464-468.
37. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003, 97(1):135-142.
38. Berenguer J., Cosin J., Miralles P., Lopez J.C., Padilla B. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. Aids 2000, 14:2946-2948.
39. Lopez-Vélez R., Videla S., Marquez M., Boix V., Jimenez-Mejias M.E., Gorgolas M., et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004, 53:540-543.
40. Bourgeois N., Lachaud L., Reynes J., Rouanet I., Mahamat A., Bastien P. Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr 2008, 48:13-19.
41. Durand R., Paul M., Pratlong F., Rivollet D., Dubreuil-Lemaire M.L., Houin R., et al. Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis. Antimicrob Agents Chemother 1998, 42:2141-2143.
42. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 2009;48:e16-22.
43. Bern C., Adler-Moore J., Berenguer J., Boelaert M., den Boer M., Davidson R.N., et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006, 43:917-924.
44. Gradoni L., Gramiccia M., Scalone A. Visceral leishmaniasis treatment. Italy. Emerg Infect Dis 2003, 9:1617-1620.
45. Gradoni L., Soteriadou K., Louzir H., Dakkak A., Toz S.O., Jaffe C., et al. Drug regimens for visceral leishmaniasis in Mediterranean countries. Trop Med Int Health 2008, 13:1272-1276.
46. Syriopoulou V., Daikos G.L., Theodoridou M., Pavlopoulou I., Manolaki A.G., Sereti E., et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003, 36:560-566.
47. Jeandel P.Y., Marty P., Roger P., Fuzibet J.G., Rosenthal E., Amphotéricine B liposomale en cure courte dans le traitement de la leishmaniose viscérale méditerranéenne de l'adulte non immunodéprimé. Rev de Mede Interne 2007, 28:44-45.
48. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001, 6:928-934.
49. Jha T.K. Drug unresponsiveness & combination therapy for kala-azar. Indian J Med Res 2006, 123:389-398.
50. Sundar S., Rai M., Chakravarty J., Agarwal D., Agrawal N., Vaillant M., et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008, 47:1000-1006.
51. Blum J., Desjeux P., Schwartz E., Beck B., Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004, 53:158-166.
52. Alrajhi A.A., Ibrahim E.A., De Vol E.B., Khairat M., Faris R.M., Maguire J.H. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002, 346:891-895.
53. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009; 3:e432.
54. Gonzalez U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008:CD005067.
55. Foulet F., Botterel F., Buffet P., Morizot G., Rivollet D., Deniau M., et al. Detection and identification of Leishmania species from clinical specimens by using a real-time PCR assay and sequencing of the cytochrome B gene. J Clin Microbiol 2007, 45:2110-2115.
56. Asilian A., Sadeghinia A., Faghihi G., Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004, 43:281-283.
57. Asilian A., Sadeghinia A., Faghihi G., Momeni A., Amini Harandi A. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 2003, 97:493-498.
58. Chaabane H., Masmoudi A., Dammak A., Kchaou W., Akrout F., Zribi M., et al. Traitement de la leishmaniose cutanée par cryothérapie associée ou non au Glucantime intra lésionnel. Ann Dermatol Venereol 2009, 136:278-279.
59. el Darouti M.A., al Rubaie S.M. Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol 1990, 29:56-59.
60. Gurei M.S., Tatli N., Ozbilge H., Erel O., Seyrek A., Kocyigit A., et al. Efficacy of cryotherapy and intralesional pentostam in treatment of cutaneous leishmaniasis. J Egypt Soc Parasitol 2000, 30:169-176.
61. Van Der Vliet D., Le Guern A.S., Freitag S., Gounod N., Therby A., Darie H., et al. Pseudomonas aeruginosa otochondritis complicating localized cutaneous leishmaniasis: prevention of mutilation by early antibiotic therapy. Am J Trop Med Hyg 2006, 75:270-272.
62. Tuon F.F., Amato V.S., Graf M.E., Siqueira A.M., Nicodemo A.C. Amato Neto V. Treatment of New World cutaneous leishmaniasis - a systematic review with a meta-analysis. Int J Dermatol 2008, 47:109-124.
63. Kim D.H., Chung H.J., Bleys J., Ghohestani R.F., Is Paromomycin an Effective and Safe Treatment against Cutaneous Leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 2009, 3:e381.
64. Lecoeur H, Buffet P, Morizot G, Goyard S, Guigon G, Milon G, et al. Optimization of topical therapy for Leishmania major localized cutaneous Leishmaniasis using a reliable C57BL/6 model. PLoS Negl Trop Dis 2007; 1:e34.
65. Lecoeur H., Buffet P.A., Milon G., Lang T. Early curative applications of aminoglycosides (WR279396) on experimental Leishmania major-loaded cutaneous site do not impair the acquisition of immunity. Antimicrob Agents Chemother 2010, 54:984-990.
66. Asilian A., Davami M. Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 2006, 31:634-637.
67. Harms G., Chehade A.K., Douba M., Roepke M., Mouakeh A., Rosenkaimer F., et al. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991, 85:214-216.
68. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous Leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3:e162.
69. Pradinaud R. Treatment of tegumentary leishmaniasis with pentamidine in French Guyana. Med Trop 1994, 54:418-422.
70. Lightburn E., Morand J.J., Meynard J.B., Kraemer P., Chaudier B., Pages F., et al. Thérapeutique des leishmanioses tégumentaires du Nouveau Monde. Expérience à propos de 326 cas traités par iséthionate de pentamidine à fortes doses. Med Trop 2003, 63:35-44.
71. Nacher M., Carme B., Sainte Marie D., Couppié P., Clyti E., Guibert P., et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2001, 95:331-336.
72. Roussel M., Nacher M., Fremont G., Rotureau B., Clyti E., Sainte-Marie D., et al. Comparison between one and two injections of pentamidine isethionate, at 7mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2006, 100:307-314.
73. Dimier-David L., Valda L., Inofuentes A., Mallea F., David C., Dedet J.P. Traitement de la lésion cutanée primaire de la leishmaniose à Leishmania braziliensis: échec de l'iséthionate de pentamidine. Med Mal Infect 1992, 22:1183-1186.
74. Berman J. Recent developments in Leishmaniasis: epidemiology diagnosis, and treatment. Curr Infect Dis Rep 2005, 7:33-38.
75. Rapp C., Imbert P., Darie H., Simon F., Gros P., Debord T., et al. Traitement par amphotéricine B liposomale d'une leishmaniose cutanée contractée à Djibouti et résistante à l'antimoniate de méglumine. Bull Soc Pathol Exot 2003, 96:209-211.
76. Brown M., Noursadeghi M., Boyle J., Davidson R.N. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 2005, 153:203-205.
77. Romero G.A., Guerra M.V., Paes M.G., Macedo V.O. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001, 65:456-465.
78. Soto J., Arana B.A., Toledo J., Rizzo N., Vega J.C., Diaz A., et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004, 38:1266-1272.
79. Arana B.A., Mendoza C.E., Rizzo N.R., Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001, 65:466-470.
80. Franke E.D., Llanos-Cuentas A., Echevarria J., Cruz M.E., Campos P., Tovar A.A., et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 1994, 51:77-82.
81. Amato V.S., Tuon F.F., Bacha H.A., Neto V.A., Nicodemo A.C. Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop 2008, 105:1-9.
82. Machado P.R., Lessa H., Lessa M., Guimarães L.H., Bang H., Ho J.L., et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007, 44:788-793.
83. Dedet J.P., Melogno R., Cardenas F., Valda L., David C., Fernandez V., et al. Rural campaign to diagnose and treat mucocutaneous leishmaniasis in Bolivia. Bull World Health Organ 1995, 73:339-345.
84. Soto J., Rea J., Valderrama M., Toledo J., Valda L., Ardiles J., et al. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. Am J Trop Med Hyg 2009, 81:387-389.
85. Soto J., Toledo J., Valda L., Valderrama M., Rea J., Parra R., et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007, 44:350-356.
86. Amato V.S., Tuon F.F., Campos A., Bacha H.A., Nicodemo A.C., Amato D., et al. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis 2007, 44:311-312.
87. Sampaio R.N., Marsden P.D. Tratamento da forma mucosa de leishmaniose sem resposta a glucantime, com anfortericina B liposomal. Rev Soc Bras Med Trop 1997, 30:125-128.
88. Guiguemde R.T., Sawadogo O.S., Bories C., Traore K.L., Nezien D., Nikiema L., et al. Leishmania major and HIV co-infection in Burkina Faso. Trans R Soc Trop Med Hyg 2003, 97:168-169.